Will Pfizer's Latest Bad News Wipe Out a Big Chunk of Its COVID Vaccine Profits?

The good times can't keep rolling forever. Pfizer (NYSE:PFE) just found that out the hard way.

Nearly everything seems to have gone Pfizer's way over the past three months. Pfizer and its partner BioNTech (NASDAQ:BNTX) reported fantastic results for their COVID-19 vaccine BNT162b2. That set the stage for the vaccine becoming the first to win Emergency Use Authorization (EUA). Pfizer and BioNTech have picked up several major supply deals, and the Biden administration appears to be seeking to strike a deal with the partners to supply another 100 million doses.